Monthly
US$200
Billed every month
Vonoprazan Fumarate Tablets(富马酸伏诺拉生片)
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 4 applicationsAccepted: 11 applicationsNo longer listed under review: 2 applicationsSupplement delivery: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders81View records ↓
Under-review filings60View records ↓
This year’s generic filers9View records ↓
NHSA approval numbers126View records ↓
API companies with A status62View records ↓
Chemical-drug catalogue
Loaded records: 81 holders; 1 in the quality-and-efficacy consistency-evaluation category, and 80 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 浙江华义制药有限公司 | 浙江华义制药有限公司 | 国药准字H20266228 | 2026/10/13 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州中化药品工业有限公司 | 苏州中化药品工业有限公司 | 国药准字H20266135 | 2026/09/29 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏诚康药业有限公司 | 江苏诚康药业有限公司 | 国药准字H20265935 | 2026/09/15 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 济南高华制药有限公司 | 济南高华制药有限公司 | 国药准字H20265915 | 2026/09/08 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 济南高华制药有限公司 | 济南高华制药有限公司 | 国药准字H20265916 | 2026/09/08 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏华阳制药有限公司 | 江苏华阳制药有限公司 | 国药准字H20265847 | 2026/09/02 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏华阳制药有限公司 | 江苏华阳制药有限公司 | 国药准字H20265848 | 2026/09/02 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 迪沙药业集团有限公司 | 迪沙药业集团有限公司 | 国药准字H20265761 | 2026/08/25 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 蚌埠丰原涂山制药有限公司 | 蚌埠丰原涂山制药有限公司 | 国药准字H20265767 | 2026/08/25 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 蚌埠丰原涂山制药有限公司 | 蚌埠丰原涂山制药有限公司 | 国药准字H20265768 | 2026/08/25 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 迪沙药业集团有限公司 | 迪沙药业集团有限公司 | 国药准字H20265762 | 2026/08/25 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江华海药业股份有限公司 | 浙江华海药业股份有限公司 | 国药准字H20265599 | 2026/08/04 | 10mg(按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江华海药业股份有限公司 | 浙江华海药业股份有限公司 | 国药准字H20265598 | 2026/08/04 | 20mg(按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | 江苏诺泰澳赛诺生物制药股份有限公司 | 国药准字H20265532 | 2026/08/04 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | 江苏诺泰澳赛诺生物制药股份有限公司 | 国药准字H20265533 | 2026/08/04 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东百诺医药股份有限公司 | 山东药石药业有限公司 | 国药准字H20265365 | 2026/07/28 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山西宝泰药业有限责任公司 | 山西宝泰药业有限责任公司 | 国药准字H20265290 | 2026/07/21 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 郑州韩都药业集团有限公司 | 郑州韩都药业集团有限公司 | 国药准字H20265283 | 2026/07/21 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山西宝泰药业有限责任公司 | 山西宝泰药业有限责任公司 | 国药准字H20265291 | 2026/07/21 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 郑州韩都药业集团有限公司 | 郑州韩都药业集团有限公司 | 国药准字H20265282 | 2026/07/21 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 陕西西岳制药有限公司 | 陕西西岳制药有限公司 | 国药准字H20265129 | 2026/07/08 | 10mg（按C17H16FN3O2S计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 陕西西岳制药有限公司 | 陕西西岳制药有限公司 | 国药准字H20265130 | 2026/07/08 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东鲁抗医药股份有限公司 | 山东鲁抗医药股份有限公司 | 国药准字H20265086 | 2026/07/08 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆世森医药科技有限公司 | 烟台鲁银药业有限公司 | 国药准字H20265109 | 2026/07/08 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆世森医药科技有限公司 | 烟台鲁银药业有限公司 | 国药准字H20265108 | 2026/07/08 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东鲁抗医药股份有限公司 | 山东鲁抗医药股份有限公司 | 国药准字H20265085 | 2026/07/08 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京北陆药业股份有限公司 | 北京北陆药业股份有限公司 | 国药准字H20264900 | 2026/06/23 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京北陆药业股份有限公司 | 北京北陆药业股份有限公司 | 国药准字H20264899 | 2026/06/23 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏中邦制药有限公司 | 江苏中邦制药有限公司 | 国药准字H20264798 | 2026/06/17 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南广升誉制药有限公司 | 江苏诚康药业有限公司 | 国药准字H20264868 | 2026/06/17 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 地奥集团成都药业股份有限公司 | 地奥集团成都药业股份有限公司 | 国药准字H20264812 | 2026/06/17 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏中邦制药有限公司 | 江苏中邦制药有限公司 | 国药准字H20264797 | 2026/06/17 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 哈药集团制药六厂 | 哈药集团技术中心 | 国药准字H20264814 | 2026/06/17 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南广升誉制药有限公司 | 江苏诚康药业有限公司 | 国药准字H20264867 | 2026/06/17 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川梓橦宫药业股份有限公司 | 四川梓橦宫药业股份有限公司 | 国药准字H20264819 | 2026/06/17 | 10mg（以C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川梓橦宫药业股份有限公司 | 四川梓橦宫药业股份有限公司 | 国药准字H20264820 | 2026/06/17 | 20mg (以C17H16FN3O2S计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 陕西白鹿制药股份有限公司 | 陕西白鹿制药股份有限公司 | 国药准字H20264873 | 2026/06/17 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 陕西白鹿制药股份有限公司 | 陕西白鹿制药股份有限公司 | 国药准字H20264872 | 2026/06/17 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 地奥集团成都药业股份有限公司 | 地奥集团成都药业股份有限公司 | 国药准字H20264811 | 2026/06/17 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 九洲生物医药（台州）有限公司 | 九洲生物医药（台州）有限公司 | 国药准字H20264738 | 2026/06/10 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 九洲生物医药（台州）有限公司 | 九洲生物医药（台州）有限公司 | 国药准字H20264739 | 2026/06/10 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东齐都药业有限公司 | 山东齐都药业有限公司 | 国药准字H20264678 | 2026/06/10 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云鹏医药集团有限公司 | 云鹏医药集团有限公司 | 国药准字H20264526 | 2026/05/27 | 10mg（按C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云鹏医药集团有限公司 | 云鹏医药集团有限公司 | 国药准字H20264527 | 2026/05/27 | 20mg（按C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州第壹制药有限公司 | 江苏利泰尔药业有限公司 | 国药准字H20264345 | 2026/05/19 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州第壹制药有限公司 | 江苏利泰尔药业有限公司 | 国药准字H20264346 | 2026/05/19 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中曦（福建）药业有限公司 | 江苏万高药业股份有限公司 | 国药准字H20264455 | 2026/05/19 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中曦（福建）药业有限公司 | 江苏万高药业股份有限公司 | 国药准字H20264456 | 2026/05/19 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江尖峰药业有限公司 | 浙江尖峰药业有限公司 | 国药准字H20264347 | 2026/05/19 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏天士力帝益药业有限公司 | 江苏天士力帝益药业有限公司 | 国药准字H20264408 | 2026/05/19 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京斯利安药业有限公司 | 北京斯利安药业有限公司 | 国药准字H20264406 | 2026/05/19 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏天士力帝益药业有限公司 | 江苏天士力帝益药业有限公司 | 国药准字H20264409 | 2026/05/19 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江尖峰药业有限公司 | 浙江尖峰药业有限公司 | 国药准字H20264348 | 2026/05/19 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东诚创蓝海医药科技有限公司 | 山东明仁福瑞达制药股份有限公司 | 国药准字H20264438 | 2026/05/19 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东诚创蓝海医药科技有限公司 | 山东明仁福瑞达制药股份有限公司 | 国药准字H20264437 | 2026/05/19 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京斯利安药业有限公司 | 北京斯利安药业有限公司 | 国药准字H20264407 | 2026/05/19 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 吉林天衡英睿制药有限公司 | 吉林天衡英睿制药有限公司 | 国药准字H20264235 | 2026/05/07 | 10mg(按C17H16FN3O2S计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 吉林天衡英睿制药有限公司 | 吉林天衡英睿制药有限公司 | 国药准字H20264234 | 2026/05/07 | 20mg(按C17H16FN3O2S计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 吉林显锋科技制药有限公司 | 吉林显锋科技制药有限公司 | 国药准字H20264195 | 2026/04/29 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 吉林显锋科技制药有限公司 | 吉林显锋科技制药有限公司 | 国药准字H20264196 | 2026/04/29 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川迪菲特药业有限公司 | 四川迪菲特药业有限公司 | 国药准字H20264008 | 2026/04/14 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 国大（吉林）制药集团有限公司 | 天津汉瑞药业有限公司 | 国药准字H20263941 | 2026/04/14 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江昂利康制药股份有限公司 | 浙江昂利康制药股份有限公司 | 国药准字H20263918 | 2026/04/14 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江昂利康制药股份有限公司 | 浙江昂利康制药股份有限公司 | 国药准字H20263919 | 2026/04/14 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽宏业药业有限公司 | 安徽宏业药业有限公司 | 国药准字H20263996 | 2026/04/14 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东诺明康药物研究院有限公司 | 济南高华制药有限公司 | 国药准字H20264024 | 2026/04/14 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 国大（吉林）制药集团有限公司 | 天津汉瑞药业有限公司 | 国药准字H20263940 | 2026/04/14 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川迪菲特药业有限公司 | 四川迪菲特药业有限公司 | 国药准字H20264007 | 2026/04/14 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽宏业药业有限公司 | 安徽宏业药业有限公司 | 国药准字H20263995 | 2026/04/14 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京易亨制药有限公司 | 南京易亨制药有限公司 | 国药准字H20264021 | 2026/04/14 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东诺明康药物研究院有限公司 | 济南高华制药有限公司 | 国药准字H20264023 | 2026/04/14 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南华纳大药厂股份有限公司 | 湖南华纳大药厂股份有限公司 | 国药准字H20263890 | 2026/04/07 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南华纳大药厂股份有限公司 | 湖南华纳大药厂股份有限公司 | 国药准字H20263891 | 2026/04/07 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都秦润医药科技有限公司 | 植恩生物技术股份有限公司 | 国药准字H20263567 | 2026/03/10 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江东亚药业股份有限公司 | 浙江东亚药业股份有限公司 | 国药准字H20263448 | 2026/02/25 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江东亚药业股份有限公司 | 浙江东亚药业股份有限公司 | 国药准字H20263447 | 2026/02/25 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天方药业有限公司 | 天方药业有限公司 | 国药准字H20263329 | 2026/02/02 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天方药业有限公司 | 天方药业有限公司 | 国药准字H20263330 | 2026/02/02 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东东阳光药业股份有限公司 | 广东东阳光药业股份有限公司 | 国药准字H20263232 | 2026/01/27 | 20mg(按C17H16FN3O2S计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天地恒一制药股份有限公司 | 天地恒一制药股份有限公司 | 国药准字H20263248 | 2026/01/27 | 20mg （按C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州中化药品工业有限公司 | 苏州中化药品工业有限公司 | 国药准字H20263194 | 2026/01/27 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东东阳光药业股份有限公司 | 广东东阳光药业股份有限公司 | 国药准字H20263233 | 2026/01/27 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 悦康药业集团股份有限公司 | 悦康药业集团股份有限公司 | 国药准字H20256450 | 2025/12/30 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州煌森生物科技有限公司 | 浙江京新药业股份有限公司 | 国药准字H20256322 | 2025/12/16 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州第三制药厂有限责任公司 | 浙江赛默制药有限公司 | 国药准字H20256249 | 2025/12/16 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州第三制药厂有限责任公司 | 浙江赛默制药有限公司 | 国药准字H20256248 | 2025/12/16 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 裕松源药业有限公司 | 裕松源药业有限公司 | 国药准字H20256288 | 2025/12/16 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京双鹭药业股份有限公司 | 北京双鹭药业股份有限公司 | 国药准字H20256220 | 2025/12/09 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海口市制药厂有限公司 | 海口市制药厂有限公司 | 国药准字H20255811 | 2025/10/28 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海口市制药厂有限公司 | 海口市制药厂有限公司 | 国药准字20255812 | 2025/10/28 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天津武田药品有限公司 | 天津武田药品有限公司 | 国药准字H20255743 | 2025/10/21 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海延安药业有限公司 | 上海延安药业有限公司 | 国药准字H20255738 | 2025/10/21 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海延安药业有限公司 | 上海延安药业有限公司 | 国药准字H20255739 | 2025/10/21 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南千金湘江药业股份有限公司 | 湖南千金湘江药业股份有限公司 | 国药准字H20255663 | 2025/09/30 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南千金湘江药业股份有限公司 | 湖南千金湘江药业股份有限公司 | 国药准字H20255662 | 2025/09/30 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆圣华曦药业股份有限公司 | 重庆圣华曦药业股份有限公司 | 国药准字H20255407 | 2025/09/09 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京正科医药股份有限公司 | 南京正科医药股份有限公司 | 国药准字H20255328 | 2025/09/02 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京正科医药股份有限公司 | 南京正科医药股份有限公司 | 国药准字H20255329 | 2025/09/02 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 双鹤药业（海南）有限责任公司 | 双鹤药业（海南）有限责任公司 | 国药准字H20255166 | 2025/08/19 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 双鹤药业（海南）有限责任公司 | 双鹤药业（海南）有限责任公司 | 国药准字H20255167 | 2025/08/19 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南皇隆制药股份有限公司 | 海南皇隆制药股份有限公司 | 国药准字H20255046 | 2025/07/29 | 20mg（按C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南皇隆制药股份有限公司 | 海南皇隆制药股份有限公司 | 国药准字H20255045 | 2025/07/29 | 10mg（按C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆迪康长江制药有限公司 | 重庆迪康长江制药有限公司 | 国药准字H20254748 | 2025/06/30 | 20mg（按C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆迪康长江制药有限公司 | 重庆迪康长江制药有限公司 | 国药准字H20254747 | 2025/06/30 | 10mg（按 C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宁波科尔康美诺华药业有限公司 | 宁波美诺华天康药业有限公司 | 国药准字H20254588 | 2025/06/17 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宁波科尔康美诺华药业有限公司 | 宁波美诺华天康药业有限公司 | 国药准字H20254587 | 2025/06/17 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华东医药（西安）博华制药有限公司 | 华东医药（西安）博华制药有限公司 | 国药准字H20254478 | 2025/06/10 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华东医药（西安）博华制药有限公司 | 华东医药（西安）博华制药有限公司 | 国药准字H20254479 | 2025/06/10 | 10mg（按C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南先施制药有限公司 | 湖南九典制药股份有限公司 | 国药准字H20254463 | 2025/06/03 | 20mg（按C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南先施制药有限公司 | 湖南九典制药股份有限公司 | 国药准字H20254464 | 2025/06/03 | 10mg（按C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州民生药业股份有限公司 | 杭州民生药业股份有限公司 | 国药准字H20254326 | 2025/05/27 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州民生药业股份有限公司 | 杭州民生药业股份有限公司 | 国药准字H20254346 | 2025/05/27 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江核力欣健药业有限公司 | 浙江核力欣健药业有限公司 | 国药准字H20254207 | 2025/05/20 | 10mg（按C17H16FN3O2S计） | Not stated by source | CDE |
| 浙江核力欣健药业有限公司 | 浙江核力欣健药业有限公司 | 国药准字H20254206 | 2025/05/20 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药集团欧意药业有限公司 | 石药集团欧意药业有限公司 | 国药准字H20254042 | 2025/04/30 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药集团欧意药业有限公司 | 石药集团欧意药业有限公司 | 国药准字H20254041 | 2025/04/30 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 正大天晴药业集团股份有限公司 | 正大天晴药业集团股份有限公司 | 国药准字H20253981 | 2025/04/22 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 正大天晴药业集团股份有限公司 | 正大天晴药业集团股份有限公司 | 国药准字H20253982 | 2025/04/22 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江康恩贝制药股份有限公司 | 浙江康恩贝制药股份有限公司 | 国药准字H20253897 | 2025/04/15 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西施美药业股份有限公司 | 江西施美药业股份有限公司 | 国药准字H20253935 | 2025/04/15 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江永太药业有限公司 | 浙江永太药业有限公司 | 国药准字H20253482 | 2025/03/04 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江永太药业有限公司 | 浙江永太药业有限公司 | 国药准字H20253481 | 2025/03/04 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东朗诺制药有限公司 | 山东朗诺制药有限公司 | 国药准字H20253457 | 2025/02/25 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东朗诺制药有限公司 | 山东朗诺制药有限公司 | 国药准字H20253458 | 2025/02/25 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20253008 | 2025/01/02 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20253007 | 2025/01/02 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 齐鲁制药（海南）有限公司 | 齐鲁制药（海南）有限公司 | 国药准字H20244399 | 2024/07/09 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 齐鲁制药（海南）有限公司 | 齐鲁制药（海南）有限公司 | 国药准字H20244400 | 2024/07/09 | 20mg（按C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宜昌人福药业有限责任公司 | 宜昌人福药业有限责任公司 | 国药准字H20244013 | 2024/06/11 | 10mg（按C17H16FN3O2S计） | Not stated by source | CDE |
| 宜昌人福药业有限责任公司 | 宜昌人福药业有限责任公司 | 国药准字H20244014 | 2024/06/11 | 20mg（按C17H16FN3O2S计） | Not stated by source | CDE |
| 四川海汇药业有限公司 | 四川海汇药业有限公司 | 国药准字H20233251 | 2023/08/31 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川海汇药业有限公司 | 四川海汇药业有限公司 | 国药准字H20233250 | 2023/08/31 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川科伦药业股份有限公司 | 四川科伦药业股份有限公司 | 国药准字H20233737 | 2023/06/21 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川科伦药业股份有限公司 | 四川科伦药业股份有限公司 | 国药准字H20233736 | 2023/06/21 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新时代药业有限公司 | 山东新时代药业有限公司 | 国药准字H20223533 | 2022/07/26 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新时代药业有限公司 | 山东新时代药业有限公司 | 国药准字H20223534 | 2022/07/26 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东齐都药业有限公司 | 山东齐都药业有限公司 | 国药准字H20264677 | 2026/06/10 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都秦润医药科技有限公司 | 植恩生物技术股份有限公司 | 国药准字H20263568 | 2026/03/10 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄龙泽制药股份有限公司 | 石家庄龙泽制药股份有限公司 | 国药准字H20254884 | 2025/07/22 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都康弘药业集团股份有限公司 | 成都康弘药业集团股份有限公司 | 国药准字H20244425 | 2024/07/09 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都康弘药业集团股份有限公司 | 成都康弘药业集团股份有限公司 | 国药准字H20244426 | 2024/07/09 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆华森制药股份有限公司 | 重庆华森制药股份有限公司 | 国药准字H20243878 | 2024/06/04 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆华森制药股份有限公司 | 重庆华森制药股份有限公司 | 国药准字H20243879 | 2024/06/04 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南海灵化学制药有限公司 | 海南海灵化学制药有限公司 | 国药准字H20266417 | 2026/10/26 | 10mg（按C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南海灵化学制药有限公司 | 海南海灵化学制药有限公司 | 国药准字H20266418 | 2026/10/26 | 20mg（按C17H16FN3O2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江诺得药业有限公司 | 浙江诺得药业有限公司 | 国药准字H20266341 | 2026/10/20 | 20mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江诺得药业有限公司 | 浙江诺得药业有限公司 | 国药准字H20266340 | 2026/10/20 | 10mg（按C17H16FN3O2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 126 distinct approval numbers and 72 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京斯利安药业有限公司 | 国药准字H20264407 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010100011 | NHSA |
| 北京北陆药业股份有限公司 | 国药准字H20264899 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010100014 | NHSA |
| 江苏天士力帝益药业有限公司 | 国药准字H20264409 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010101500 | NHSA |
| 江苏中邦制药有限公司 | 国药准字H20264797 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010101525 | NHSA |
| 苏州第壹制药有限公司 | 国药准字H20264345 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010101649 | NHSA |
| 苏州中化药品工业有限公司 | 国药准字H20263194 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010101679 | NHSA |
| 四川迪菲特药业有限公司 | 国药准字H20264007 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010102064 | NHSA |
| 地奥集团成都药业股份有限公司 | 国药准字H20264811 | 10mg(按 C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010102089 | NHSA |
| 四川梓橦宫药业股份有限公司 | 国药准字H20264820 | 20mg (按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010102300 | NHSA |
| 陕西白鹿制药股份有限公司 | 国药准字H20264872 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010102353 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20265129 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010102439 | NHSA |
| 山西宝泰药业有限责任公司 | 国药准字H20265290 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010102871 | NHSA |
| 天方药业有限公司 | 国药准字H20263329 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010103098 | NHSA |
| 郑州韩都药业集团有限公司 | 国药准字H20265283 | 20mg(按 C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010103251 | NHSA |
| 吉林显锋科技制药有限公司 | 国药准字H20264195 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010103298 | NHSA |
| 哈药集团制药六厂 | 国药准字H20264814 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010103710 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20264677 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010104145 | NHSA |
| 安徽宏业药业有限公司 | 国药准字H20263995 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010104373 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20263918 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010104606 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20265599 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010104647 | NHSA |
| 浙江尖峰药业有限公司 | 国药准字H20264347 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010104655 | NHSA |
| 海南葫芦娃药业集团股份有限公司 | 国药准字H20265459 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010105789 | NHSA |
| 广东东阳光药业股份有限公司 | 国药准字H20263232 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010106988 | NHSA |
| 浙江东亚药业股份有限公司 | 国药准字H20263448 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010179285 | NHSA |
| 天地恒一制药股份有限公司 | 国药准字H20263248 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010180086 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20264867 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010181251 | NHSA |
| 山东百诺医药股份有限公司 | 国药准字H20265365 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010183011 | NHSA |
| 迪沙药业集团有限公司 | 国药准字H20265762 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010183063 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20265086 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010183198 | NHSA |
| 国大(吉林)制药集团有限公司 | 国药准字H20263940 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010183254 | NHSA |
| 重庆世森医药科技有限公司 | 国药准字H20265108 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010183546 | NHSA |
| 九洲生物医药(台州)有限公司 | 国药准字H20264739 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010183758 | NHSA |
| 吉林天衡英睿制药有限公司 | 国药准字H20264234 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010183805 | NHSA |
| 济南高华制药有限公司 | 国药准字H20265915 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010185352 | NHSA |
| 成都秦润医药科技有限公司 | 国药准字H20263567 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010185523 | NHSA |
| 苏州第壹制药有限公司 | 国药准字H20264345 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010201649 | NHSA |
| 苏州中化药品工业有限公司 | 国药准字H20263194 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010201679 | NHSA |
| 四川梓橦宫药业股份有限公司 | 国药准字H20264820 | 20mg (按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010202300 | NHSA |
| 天方药业有限公司 | 国药准字H20263329 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010203098 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20263918 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010204606 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20265599 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010204647 | NHSA |
| 浙江东亚药业股份有限公司 | 国药准字H20263448 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010279285 | NHSA |
| 天地恒一制药股份有限公司 | 国药准字H20263248 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010280086 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20264867 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010281251 | NHSA |
| 山东百诺医药股份有限公司 | 国药准字H20265365 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010283011 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20265086 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010283198 | NHSA |
| 重庆世森医药科技有限公司 | 国药准字H20265108 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010283546 | NHSA |
| 九洲生物医药(台州)有限公司 | 国药准字H20264739 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010283758 | NHSA |
| 吉林天衡英睿制药有限公司 | 国药准字H20264234 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010283805 | NHSA |
| 济南高华制药有限公司 | 国药准字H20265915 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010285352 | NHSA |
| 苏州第壹制药有限公司 | 国药准字H20264345 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010301649 | NHSA |
| 苏州中化药品工业有限公司 | 国药准字H20263194 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010301679 | NHSA |
| 四川梓橦宫药业股份有限公司 | 国药准字H20264820 | 20mg (按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010302300 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20265599 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010304647 | NHSA |
| 浙江东亚药业股份有限公司 | 国药准字H20263448 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010379285 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20264867 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010381251 | NHSA |
| 山东百诺医药股份有限公司 | 国药准字H20265365 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010383011 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20265086 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010383198 | NHSA |
| 重庆世森医药科技有限公司 | 国药准字H20265108 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010383546 | NHSA |
| 吉林天衡英睿制药有限公司 | 国药准字H20264234 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010383805 | NHSA |
| 济南高华制药有限公司 | 国药准字H20265915 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010385352 | NHSA |
| 中曦(福建)药业有限公司 | 国药准字H20264455 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010401503 | NHSA |
| 苏州中化药品工业有限公司 | 国药准字H20263194 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010401679 | NHSA |
| 四川梓橦宫药业股份有限公司 | 国药准字H20264820 | 20mg (按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010402300 | NHSA |
| 浙江东亚药业股份有限公司 | 国药准字H20263448 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010479285 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20264867 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010481251 | NHSA |
| 山东百诺医药股份有限公司 | 国药准字H20265365 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010483011 | NHSA |
| 重庆世森医药科技有限公司 | 国药准字H20265108 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010483546 | NHSA |
| 吉林天衡英睿制药有限公司 | 国药准字H20264234 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010483805 | NHSA |
| 济南高华制药有限公司 | 国药准字H20265915 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010485352 | NHSA |
| 中曦(福建)药业有限公司 | 国药准字H20264455 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010501503 | NHSA |
| 重庆世森医药科技有限公司 | 国药准字H20265108 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010583546 | NHSA |
| 济南高华制药有限公司 | 国药准字H20265915 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010585352 | NHSA |
| 中曦(福建)药业有限公司 | 国药准字H20264455 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010601503 | NHSA |
| 济南高华制药有限公司 | 国药准字H20265915 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010685352 | NHSA |
| 中曦(福建)药业有限公司 | 国药准字H20264455 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010701503 | NHSA |
| 济南高华制药有限公司 | 国药准字H20265915 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010785352 | NHSA |
| 中曦(福建)药业有限公司 | 国药准字H20264455 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010801503 | NHSA |
| 济南高华制药有限公司 | 国药准字H20265915 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010885352 | NHSA |
| 济南高华制药有限公司 | 国药准字H20265915 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010985352 | NHSA |
| 济南高华制药有限公司 | 国药准字H20265915 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001011085352 | NHSA |
| 济南高华制药有限公司 | 国药准字H20265915 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001011185352 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H20264406 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020100011 | NHSA |
| 北京北陆药业股份有限公司 | 国药准字H20264900 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020100014 | NHSA |
| 江苏天士力帝益药业有限公司 | 国药准字H20264408 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020101500 | NHSA |
| 江苏中邦制药有限公司 | 国药准字H20264798 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020101525 | NHSA |
| 苏州第壹制药有限公司 | 国药准字H20264346 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020101649 | NHSA |
| 苏州中化药品工业有限公司 | 国药准字H20266135 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020101679 | NHSA |
| 四川迪菲特药业有限公司 | 国药准字H20264008 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020102064 | NHSA |
| 地奥集团成都药业股份有限公司 | 国药准字H20264812 | 20mg((按 C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020102089 | NHSA |
| 四川梓橦宫药业股份有限公司 | 国药准字H20264819 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020102300 | NHSA |
| 陕西白鹿制药股份有限公司 | 国药准字H20264873 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020102353 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20265130 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020102439 | NHSA |
| 山西宝泰药业有限责任公司 | 国药准字H20265290 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020102871 | NHSA |
| 天方药业有限公司 | 国药准字H20263330 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020103098 | NHSA |
| 吉林显锋科技制药有限公司 | 国药准字H20264196 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020103298 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20264678 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020104145 | NHSA |
| 安徽宏业药业有限公司 | 国药准字H20263996 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020104373 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20263919 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020104606 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20265598 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020104647 | NHSA |
| 浙江尖峰药业有限公司 | 国药准字H20264348 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020104655 | NHSA |
| 海南葫芦娃药业集团股份有限公司 | 国药准字H20265460 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020105789 | NHSA |
| 广东东阳光药业股份有限公司 | 国药准字H20263233 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020106988 | NHSA |
| 浙江东亚药业股份有限公司 | 国药准字H20263447 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020179285 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20264868 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020181251 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20265085 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020183198 | NHSA |
| 国大(吉林)制药集团有限公司 | 国药准字H20263941 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020183254 | NHSA |
| 重庆世森医药科技有限公司 | 国药准字H20265109 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020183546 | NHSA |
| 九洲生物医药(台州)有限公司 | 国药准字H20264738 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020183758 | NHSA |
| 吉林天衡英睿制药有限公司 | 国药准字H20264235 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020183805 | NHSA |
| 成都秦润医药科技有限公司 | 国药准字H20263568 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020185523 | NHSA |
| 江苏天士力帝益药业有限公司 | 国药准字H20264408 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020201500 | NHSA |
| 苏州第壹制药有限公司 | 国药准字H20264346 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020201649 | NHSA |
| 苏州中化药品工业有限公司 | 国药准字H20266135 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020201679 | NHSA |
| 四川迪菲特药业有限公司 | 国药准字H20264008 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020202064 | NHSA |
| 四川梓橦宫药业股份有限公司 | 国药准字H20264819 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020202300 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20265130 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020202439 | NHSA |
| 山西宝泰药业有限责任公司 | 国药准字H20265290 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020202871 | NHSA |
| 天方药业有限公司 | 国药准字H20263330 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020203098 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20263919 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020204606 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20265598 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020204647 | NHSA |
| 浙江东亚药业股份有限公司 | 国药准字H20263447 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020279285 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20264868 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020281251 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20265085 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020283198 | NHSA |
| 重庆世森医药科技有限公司 | 国药准字H20265109 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020283546 | NHSA |
| 九洲生物医药(台州)有限公司 | 国药准字H20264738 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020283758 | NHSA |
| 中曦(福建)药业有限公司 | 国药准字H20264456 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020301503 | NHSA |
| 苏州第壹制药有限公司 | 国药准字H20264346 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020301649 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20265130 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020302439 | NHSA |
| 山西宝泰药业有限责任公司 | 国药准字H20265290 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020302871 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20265598 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020304647 | NHSA |
| 浙江东亚药业股份有限公司 | 国药准字H20263447 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020379285 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20264868 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020381251 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20265085 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020383198 | NHSA |
| 重庆世森医药科技有限公司 | 国药准字H20265109 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020383546 | NHSA |
| 中曦(福建)药业有限公司 | 国药准字H20264456 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020401503 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20265130 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020402439 | NHSA |
| 山西宝泰药业有限责任公司 | 国药准字H20265290 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020402871 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20265598 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020404647 | NHSA |
| 浙江东亚药业股份有限公司 | 国药准字H20263447 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020479285 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20264868 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020481251 | NHSA |
| 重庆世森医药科技有限公司 | 国药准字H20265109 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020483546 | NHSA |
| 中曦(福建)药业有限公司 | 国药准字H20264456 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020501503 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20265130 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020502439 | NHSA |
| 山西宝泰药业有限责任公司 | 国药准字H20265290 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020502871 | NHSA |
| 重庆世森医药科技有限公司 | 国药准字H20265109 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020583546 | NHSA |
| 中曦(福建)药业有限公司 | 国药准字H20264456 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020601503 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20265130 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020602439 | NHSA |
| 山西宝泰药业有限责任公司 | 国药准字H20265290 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020602871 | NHSA |
| 中曦(福建)药业有限公司 | 国药准字H20264456 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020701503 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20265130 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020702439 | NHSA |
| 山西宝泰药业有限责任公司 | 国药准字H20265290 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020702871 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20265130 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020802439 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20265130 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020902439 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20265130 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001021002439 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20265130 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001021102439 | NHSA |
| 国大(吉林)制药集团有限公司 | 国药准字H20263941 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001030183254 | NHSA |
| 吉林天衡英睿制药有限公司 | 国药准字H20264235 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001030183805 | NHSA |
| 国大(吉林)制药集团有限公司 | 国药准字H20263941 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001030283254 | NHSA |
| 吉林天衡英睿制药有限公司 | 国药准字H20264235 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001040183805 | NHSA |
| 吉林天衡英睿制药有限公司 | 国药准字H20264235 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001050183805 | NHSA |
| 北京双鹭药业股份有限公司 | 国药准字H20256220 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010100148 | NHSA |
| 悦康药业集团股份有限公司 | 国药准字H20256450 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010100239 | NHSA |
| 上海延安药业有限公司 | 国药准字H20255738 | 10mg( 按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010100812 | NHSA |
| 重庆迪康长江制药有限公司 | 国药准字H20254747 | 10mg(按 C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010100993 | NHSA |
| 常州四药制药有限公司 | 国药准字H20255969 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010101389 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20253393 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010101503 | NHSA |
| 正大天晴药业集团股份有限公司 | 国药准字H20253982 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010101523 | NHSA |
| 南京正科医药股份有限公司 | 国药准字H20255329 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010101599 | NHSA |
| 苏州第三制药厂有限责任公司 | 国药准字H20256249 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010101646 | NHSA |
| 华东医药(西安)博华制药有限公司 | 国药准字H20254478 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010102469 | NHSA |
| 石家庄四药有限公司 | 国药准字H20253007 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010102763 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20254041 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010102770 | NHSA |
| 山东福瑞达医药集团有限公司 | 国药准字H20256288 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010103163 | NHSA |
| 杭州民生药业股份有限公司 | 国药准字H20254346 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010104494 | NHSA |
| 浙江康恩贝制药股份有限公司 | 国药准字H20253896 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010104670 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20255663 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010104960 | NHSA |
| 江西施美药业股份有限公司 | 国药准字H20253935 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010105356 | NHSA |
| 海口市制药厂有限公司 | 国药准字H20255811 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010105758 | NHSA |
| 海南皇隆制药股份有限公司 | 国药准字H20255046 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010105781 | NHSA |
| 双鹤药业(海南)有限责任公司 | 国药准字H20255167 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010105843 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20255407 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010109568 | NHSA |
| 山西振东制药股份有限公司 | 国药准字H20253457 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010110323 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20254884 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010179261 | NHSA |
| 浙江核力欣健药业有限公司 | 国药准字H20254206 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010180406 | NHSA |
| 浙江永太药业有限公司 | 国药准字H20253482 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010181012 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20254464 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010184106 | NHSA |
| 杭州煌森生物科技有限公司 | 国药准字H20256322 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010184216 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254587 | 10mg(按C17H16FN3O2S计) | Category B (乙) | XA02BCF721A001010184240 | NHSA |
| 北京双鹭药业股份有限公司 | 国药准字H20256220 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010200148 | NHSA |
| 重庆迪康长江制药有限公司 | 国药准字H20254747 | 10mg(按 C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010200993 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20253393 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010201503 | NHSA |
| 正大天晴药业集团股份有限公司 | 国药准字H20253982 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010201523 | NHSA |
| 南京正科医药股份有限公司 | 国药准字H20255329 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010201599 | NHSA |
| 苏州第三制药厂有限责任公司 | 国药准字H20256249 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010201646 | NHSA |
| 华东医药(西安)博华制药有限公司 | 国药准字H20254478 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010202469 | NHSA |
| 山东福瑞达医药集团有限公司 | 国药准字H20256288 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010203163 | NHSA |
| 江西施美药业股份有限公司 | 国药准字H20253935 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010205356 | NHSA |
| 海口市制药厂有限公司 | 国药准字H20255811 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010205758 | NHSA |
| 海南皇隆制药股份有限公司 | 国药准字H20255046 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010205781 | NHSA |
| 双鹤药业(海南)有限责任公司 | 国药准字H20255167 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010205843 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20255407 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010209568 | NHSA |
| 山西振东制药股份有限公司 | 国药准字H20253457 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010210323 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20254884 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010279261 | NHSA |
| 浙江核力欣健药业有限公司 | 国药准字H20254206 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010280406 | NHSA |
| 浙江永太药业有限公司 | 国药准字H20253482 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010281012 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20254464 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010284106 | NHSA |
| 杭州煌森生物科技有限公司 | 国药准字H20256322 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010284216 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254587 | 10mg(按C17H16FN3O2S计) | Category B (乙) | XA02BCF721A001010284240 | NHSA |
| 北京双鹭药业股份有限公司 | 国药准字H20256220 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010300148 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20253393 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010301503 | NHSA |
| 正大天晴药业集团股份有限公司 | 国药准字H20253982 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010301523 | NHSA |
| 苏州第三制药厂有限责任公司 | 国药准字H20256249 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010301646 | NHSA |
| 海南皇隆制药股份有限公司 | 国药准字H20255046 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010305781 | NHSA |
| 双鹤药业(海南)有限责任公司 | 国药准字H20255167 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010305843 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20255407 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010309568 | NHSA |
| 山西振东制药股份有限公司 | 国药准字H20253457 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010310323 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20254884 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010379261 | NHSA |
| 浙江核力欣健药业有限公司 | 国药准字H20254206 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010380406 | NHSA |
| 浙江永太药业有限公司 | 国药准字H20253482 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010381012 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20254464 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010384106 | NHSA |
| 杭州煌森生物科技有限公司 | 国药准字H20256322 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010384216 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254587 | 10mg(按C17H16FN3O2S计) | Category B (乙) | XA02BCF721A001010384240 | NHSA |
| 双鹤药业(海南)有限责任公司 | 国药准字H20255167 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010405843 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20255407 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010409568 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20254884 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010479261 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20254464 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010484106 | NHSA |
| 杭州煌森生物科技有限公司 | 国药准字H20256322 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001010484216 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254587 | 10mg(按C17H16FN3O2S计) | Category B (乙) | XA02BCF721A001010484240 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20255407 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010509568 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254587 | 10mg(按C17H16FN3O2S计) | Category B (乙) | XA02BCF721A001010584240 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254587 | 10mg(按C17H16FN3O2S计) | Category B (乙) | XA02BCF721A001010684240 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254587 | 10mg(按C17H16FN3O2S计) | Category B (乙) | XA02BCF721A001010784240 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254587 | 10mg(按C17H16FN3O2S计) | Category B (乙) | XA02BCF721A001010884240 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20253393 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010901503 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20253393 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001011001503 | NHSA |
| 上海延安药业有限公司 | 国药准字H20255739 | 20mg( 按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020100812 | NHSA |
| 重庆迪康长江制药有限公司 | 国药准字H20254748 | 20mg(按 C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020100993 | NHSA |
| 常州四药制药有限公司 | 国药准字H20255968 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020101389 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20253394 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020101503 | NHSA |
| 正大天晴药业集团股份有限公司 | 国药准字H20253981 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020101523 | NHSA |
| 苏州第三制药厂有限责任公司 | 国药准字H20256248 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020101646 | NHSA |
| 华东医药(西安)博华制药有限公司 | 国药准字H20254479 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020102469 | NHSA |
| 石家庄四药有限公司 | 国药准字H20253008 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020102763 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20254042 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020102770 | NHSA |
| 杭州民生药业股份有限公司 | 国药准字H20254326 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020104494 | NHSA |
| 浙江康恩贝制药股份有限公司 | 国药准字H20253897 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020104670 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20255662 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020104960 | NHSA |
| 江西施美药业股份有限公司 | 国药准字H20253936 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020105356 | NHSA |
| 海口市制药厂有限公司 | 国药准字H20255812 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020105758 | NHSA |
| 海南皇隆制药股份有限公司 | 国药准字H20255045 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020105781 | NHSA |
| 双鹤药业(海南)有限责任公司 | 国药准字H20255166 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020105843 | NHSA |
| 天津武田药品有限公司 | 国药准字H20255743 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020110289 | NHSA |
| 山西振东制药股份有限公司 | 国药准字H20253458 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020110323 | NHSA |
| 浙江核力欣健药业有限公司 | 国药准字H20254207 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020180406 | NHSA |
| 浙江永太药业有限公司 | 国药准字H20253481 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020181012 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20254463 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020184106 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254588 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020184240 | NHSA |
| 上海延安药业有限公司 | 国药准字H20255739 | 20mg( 按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020200812 | NHSA |
| 重庆迪康长江制药有限公司 | 国药准字H20254748 | 20mg(按 C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020200993 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20253394 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020201503 | NHSA |
| 正大天晴药业集团股份有限公司 | 国药准字H20253981 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020201523 | NHSA |
| 苏州第三制药厂有限责任公司 | 国药准字H20256248 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020201646 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20254042 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020202770 | NHSA |
| 江西施美药业股份有限公司 | 国药准字H20253936 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020205356 | NHSA |
| 海口市制药厂有限公司 | 国药准字H20255812 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020205758 | NHSA |
| 双鹤药业(海南)有限责任公司 | 国药准字H20255166 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020205843 | NHSA |
| 山西振东制药股份有限公司 | 国药准字H20253458 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020210323 | NHSA |
| 浙江核力欣健药业有限公司 | 国药准字H20254207 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020280406 | NHSA |
| 浙江永太药业有限公司 | 国药准字H20253481 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020281012 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20254463 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020284106 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254588 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020284240 | NHSA |
| 正大天晴药业集团股份有限公司 | 国药准字H20253981 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020301523 | NHSA |
| 苏州第三制药厂有限责任公司 | 国药准字H20256248 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020301646 | NHSA |
| 海口市制药厂有限公司 | 国药准字H20255812 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020305758 | NHSA |
| 双鹤药业(海南)有限责任公司 | 国药准字H20255166 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020305843 | NHSA |
| 山西振东制药股份有限公司 | 国药准字H20253458 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020310323 | NHSA |
| 浙江永太药业有限公司 | 国药准字H20253481 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020381012 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20254463 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020384106 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254588 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020384240 | NHSA |
| 海口市制药厂有限公司 | 国药准字H20255812 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020405758 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20254463 | 20mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001020484106 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254588 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020484240 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254588 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020584240 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20254588 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020684240 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20253394 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020801503 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20254464 | 10mg(按C₁₇H₁₆FN₃O₂S 计) | Category B (乙) | XA02BCF721A001030184106 | NHSA |
| 重庆华森制药股份有限公司 | 国药准字H20243879 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010101007 | NHSA |
| 成都康弘药业集团股份有限公司 | 国药准字H20244425 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010102016 | NHSA |
| 四川科伦药业股份有限公司 | 国药准字H20233737 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010102180 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20223533 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010104188 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20244400 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010105847 | NHSA |
| Takeda Pharmaceutical Company Limited | 国药准字J20200011 | 按C17H16FN3O2S计 20mg | Category B (乙) | XA02BCF721A001010110289 | NHSA |
| Takeda Pharmaceutical Company Limited | 国药准字HJ20190065 | 按C₁₇H₁₆FN₃O₂S计20mg | Category B (乙) | XA02BCF721A001010179133 | NHSA |
| 重庆华森制药股份有限公司 | 国药准字H20243879 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010201007 | NHSA |
| 成都康弘药业集团股份有限公司 | 国药准字H20244425 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010202016 | NHSA |
| 四川科伦药业股份有限公司 | 国药准字H20233737 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010202180 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20223533 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010204188 | NHSA |
| Takeda Pharmaceutical Company Limited | 国药准字J20200011 | 按C17H16FN3O2S计 20mg | Category B (乙) | XA02BCF721A001010210289 | NHSA |
| Takeda Pharmaceutical Company Limited | 国药准字HJ20190065 | 按C₁₇H₁₆FN₃O₂S计20mg | Category B (乙) | XA02BCF721A001010279133 | NHSA |
| 重庆华森制药股份有限公司 | 国药准字H20243879 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010301007 | NHSA |
| 成都康弘药业集团股份有限公司 | 国药准字H20244425 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010302016 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20223533 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010304188 | NHSA |
| Takeda Pharmaceutical Company Limited | 国药准字HJ20190065 | 按C₁₇H₁₆FN₃O₂S计20mg | Category B (乙) | XA02BCF721A001010379133 | NHSA |
| 重庆华森制药股份有限公司 | 国药准字H20243879 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010401007 | NHSA |
| 成都康弘药业集团股份有限公司 | 国药准字H20244425 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010402016 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20223533 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010404188 | NHSA |
| 重庆华森制药股份有限公司 | 国药准字H20243879 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010501007 | NHSA |
| 成都康弘药业集团股份有限公司 | 国药准字H20244425 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010502016 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20223533 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010504188 | NHSA |
| 重庆华森制药股份有限公司 | 国药准字H20243879 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010601007 | NHSA |
| 成都康弘药业集团股份有限公司 | 国药准字H20244425 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010602016 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20223533 | 10mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010604188 | NHSA |
| 成都康弘药业集团股份有限公司 | 国药准字H20244426 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020102016 | NHSA |
| 四川科伦药业股份有限公司 | 国药准字H20233736 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020102180 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20223534 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020104188 | NHSA |
| 成都康弘药业集团股份有限公司 | 国药准字H20244426 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020202016 | NHSA |
| 四川科伦药业股份有限公司 | 国药准字H20233736 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020202180 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20223534 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020204188 | NHSA |
| 成都康弘药业集团股份有限公司 | 国药准字H20244426 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020302016 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20223534 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020304188 | NHSA |
| 成都康弘药业集团股份有限公司 | 国药准字H20244426 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020402016 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20223534 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020404188 | NHSA |
| 成都康弘药业集团股份有限公司 | 国药准字H20244426 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020502016 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20223534 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020504188 | NHSA |
| 成都康弘药业集团股份有限公司 | 国药准字H20244426 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020602016 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20223534 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001020604188 | NHSA |
| 江苏诚康药业有限公司 | 国药准字H20265935 | 20mg(按C₁₇H₁₆FN₃O₂S计) | Category B (乙) | XA02BCF721A001010182219 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 60 filings and 34 distinct first applicants.
Generic 49 · Supplement 11
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 沐邦（北京）医药科技有限公司;江苏永安制药有限公司 | CYHS2600362 | Generic | 2026/02/04 | Not stated by source | CDE |
| 沐邦（北京）医药科技有限公司;江苏永安制药有限公司 | CYHS2600361 | Generic | 2026/02/04 | Not stated by source | CDE |
| 江苏恒沣药业有限公司;扬子江药业集团江苏紫龙药业有限公司 | CYHS2601317 | Generic | 2026/06/05 | Not stated by source | CDE |
| 江苏恒沣药业有限公司;扬子江药业集团江苏紫龙药业有限公司 | CYHS2601316 | Generic | 2026/06/05 | Not stated by source | CDE |
| 江苏神华药业有限公司 | CYHS2503240 | Generic | 2025/09/03 | Not stated by source | CDE |
| 江苏东科康德药业有限公司;南京集萃剂鼎医药有限公司 | CYHS2503056 | Generic | 2025/08/20 | Not stated by source | CDE |
| 四川依科制药有限公司 | CYHS2602255 | Generic | 2026/09/10 | Not stated by source | CDE |
| 四川依科制药有限公司 | CYHS2602254 | Generic | 2026/09/10 | Not stated by source | CDE |
| 天津武田药品有限公司 | CYHB2601625 | Supplement | 2026/08/25 | Not stated by source | CDE |
| Takeda Pharmaceutical Company Limited;Takeda Pharmaceutical Company Limited Hikari Plant;Tianjin Takeda Pharmaceutical Company Limited | JYHB2600472 | Supplement | 2026/08/14 | Not stated by source | CDE |
| Takeda Pharmaceutical Company Limited;Takeda Pharmaceutical Company Limited Hikari Plant | JYHB2600471 | Supplement | 2026/08/14 | Not stated by source | CDE |
| Takeda Pharmaceutical Company Limited;Takeda Pharmaceutical Company Limited Hikari Plant;Tianjin Takeda Pharmaceutical Company Limited | JYHB2600470 | Supplement | 2026/08/14 | Not stated by source | CDE |
| Takeda Pharmaceutical Company Limited;Takeda Pharmaceutical Company Limited Hikari Plant | JYHB2600469 | Supplement | 2026/08/14 | Not stated by source | CDE |
| 宁波科尔康美诺华药业有限公司;宁波美诺华天康药业有限公司 | CYHB2601495 | Supplement | 2026/08/04 | Not stated by source | CDE |
| 宁波科尔康美诺华药业有限公司;宁波美诺华天康药业有限公司 | CYHB2601494 | Supplement | 2026/08/04 | Not stated by source | CDE |
| 山东新时代药业有限公司 | CYHB2601413 | Supplement | 2026/07/24 | Not stated by source | CDE |
| 山东新时代药业有限公司 | CYHB2601412 | Supplement | 2026/07/24 | Not stated by source | CDE |
| 山东方明药业集团股份有限公司 | CYHS2601758 | Generic | 2026/07/22 | Not stated by source | CDE |
| 山东方明药业集团股份有限公司 | CYHS2601756 | Generic | 2026/07/22 | Not stated by source | CDE |
| 江西科睿药业有限公司 | CYHB2601185 | Supplement | 2026/06/25 | Not stated by source | CDE |
| 江西科睿药业有限公司 | CYHB2601184 | Supplement | 2026/06/25 | Not stated by source | CDE |
| 山东益健药业有限公司 | CYHS2601411 | Generic | 2026/06/15 | Not stated by source | CDE |
| 广东彼迪药业有限公司 | CYHS2601313 | Generic | 2026/06/05 | Not stated by source | CDE |
| 广东彼迪药业有限公司 | CYHS2601312 | Generic | 2026/06/05 | Not stated by source | CDE |
| 新乡市常乐制药有限责任公司;天津天士力圣特制药有限公司 | CYHS2600976 | Generic | 2026/04/28 | Not stated by source | CDE |
| 上海衡山药业有限公司 | CYHS2600820 | Generic | 2026/04/09 | Not stated by source | CDE |
| 上海衡山药业有限公司 | CYHS2600819 | Generic | 2026/04/09 | Not stated by source | CDE |
| 广州白云山天心制药股份有限公司 | CYHS2504458 | Generic | 2025/12/30 | Not stated by source | CDE |
| 新石阳光药业（河北）有限公司 | CYHS2504447 | Generic | 2025/12/27 | Not stated by source | CDE |
| 新石阳光药业（河北）有限公司 | CYHS2504446 | Generic | 2025/12/27 | Not stated by source | CDE |
| 北京康立生医药技术开发有限公司;山东威智百科药业有限公司 | CYHS2503893 | Generic | 2025/11/06 | Not stated by source | CDE |
| 北京康立生医药技术开发有限公司;山东威智百科药业有限公司 | CYHS2503892 | Generic | 2025/11/06 | Not stated by source | CDE |
| 南昌市飞弘药业有限公司 | CYHS2503830 | Generic | 2025/10/29 | Not stated by source | CDE |
| 南昌市飞弘药业有限公司 | CYHS2503829 | Generic | 2025/10/29 | Not stated by source | CDE |
| 四川森科制药有限公司 | CYHS2503711 | Generic | 2025/10/16 | Not stated by source | CDE |
| 四川森科制药有限公司 | CYHS2503710 | Generic | 2025/10/16 | Not stated by source | CDE |
| 珠海同源药业有限公司 | CYHS2503695 | Generic | 2025/10/16 | Not stated by source | CDE |
| 珠海同源药业有限公司 | CYHS2503694 | Generic | 2025/10/16 | Not stated by source | CDE |
| 药大制药有限公司 | CYHS2503021 | Generic | 2025/08/19 | Not stated by source | CDE |
| 药大制药有限公司 | CYHS2503018 | Generic | 2025/08/19 | Not stated by source | CDE |
| 湖南迪诺制药股份有限公司 | CYHS2502849 | Generic | 2025/08/06 | Not stated by source | CDE |
| 山东铂源药业股份有限公司;山东丰金生物医药有限公司 | CYHS2502751 | Generic | 2025/07/30 | Not stated by source | CDE |
| 山东铂源药业股份有限公司;山东丰金生物医药有限公司 | CYHS2502750 | Generic | 2025/07/30 | Not stated by source | CDE |
| 江西山香药业有限公司;江西科睿药业有限公司 | CYHS2502455 | Generic | 2025/07/09 | Not stated by source | CDE |
| 江西山香药业有限公司;江西科睿药业有限公司 | CYHS2502454 | Generic | 2025/07/09 | Not stated by source | CDE |
| 山东新华制药股份有限公司;新华制药（高密）有限公司 | CYHS2502271 | Generic | 2025/06/25 | Not stated by source | CDE |
| 昆明源瑞制药有限公司 | CYHS2502255 | Generic | 2025/06/23 | Not stated by source | CDE |
| 昆明源瑞制药有限公司 | CYHS2502253 | Generic | 2025/06/23 | Not stated by source | CDE |
| 山东普瑞曼药业有限公司 | CYHS2501584 | Generic | 2025/04/28 | Not stated by source | CDE |
| 福建品腾药业有限公司;湖南九典制药股份有限公司 | CYHS2501537 | Generic | 2025/04/24 | Not stated by source | CDE |
| 福建品腾药业有限公司;湖南九典制药股份有限公司 | CYHS2501536 | Generic | 2025/04/24 | Not stated by source | CDE |
| 济南明鑫制药股份有限公司 | CYHS2501376 | Generic | 2025/04/10 | Not stated by source | CDE |
| 济南明鑫制药股份有限公司 | CYHS2501375 | Generic | 2025/04/10 | Not stated by source | CDE |
| 合肥英太制药有限公司 | CYHS2401483 | Generic | 2024/05/17 | Not stated by source | CDE |
| 合肥英太制药有限公司 | CYHS2401482 | Generic | 2024/05/17 | Not stated by source | CDE |
| 福建省宝诺医药研发有限公司;浙江京新药业股份有限公司 | CYHS2401466 | Generic | 2024/05/15 | Not stated by source | CDE |
| 四川制药制剂有限公司 | CYHS2400452 | Generic | 2024/02/03 | Not stated by source | CDE |
| 四川制药制剂有限公司 | CYHS2400451 | Generic | 2024/02/03 | Not stated by source | CDE |
| 华北制药集团新药研究开发有限责任公司;华北制药河北华诺有限公司 | CYHS2602736 | Generic | 2026/11/09 | Not stated by source | CDE |
| 华北制药集团新药研究开发有限责任公司;华北制药河北华诺有限公司 | CYHS2602735 | Generic | 2026/11/09 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 16 filings and 9 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 沐邦（北京）医药科技有限公司;江苏永安制药有限公司 | CYHS2600362 | Generic | 2026/02/04 | Not stated by source | CDE |
| 沐邦（北京）医药科技有限公司;江苏永安制药有限公司 | CYHS2600361 | Generic | 2026/02/04 | Not stated by source | CDE |
| 江苏恒沣药业有限公司;扬子江药业集团江苏紫龙药业有限公司 | CYHS2601317 | Generic | 2026/06/05 | Not stated by source | CDE |
| 江苏恒沣药业有限公司;扬子江药业集团江苏紫龙药业有限公司 | CYHS2601316 | Generic | 2026/06/05 | Not stated by source | CDE |
| 四川依科制药有限公司 | CYHS2602255 | Generic | 2026/09/10 | Not stated by source | CDE |
| 四川依科制药有限公司 | CYHS2602254 | Generic | 2026/09/10 | Not stated by source | CDE |
| 山东方明药业集团股份有限公司 | CYHS2601758 | Generic | 2026/07/22 | Not stated by source | CDE |
| 山东方明药业集团股份有限公司 | CYHS2601756 | Generic | 2026/07/22 | Not stated by source | CDE |
| 山东益健药业有限公司 | CYHS2601411 | Generic | 2026/06/15 | Not stated by source | CDE |
| 广东彼迪药业有限公司 | CYHS2601313 | Generic | 2026/06/05 | Not stated by source | CDE |
| 广东彼迪药业有限公司 | CYHS2601312 | Generic | 2026/06/05 | Not stated by source | CDE |
| 新乡市常乐制药有限责任公司;天津天士力圣特制药有限公司 | CYHS2600976 | Generic | 2026/04/28 | Not stated by source | CDE |
| 上海衡山药业有限公司 | CYHS2600820 | Generic | 2026/04/09 | Not stated by source | CDE |
| 上海衡山药业有限公司 | CYHS2600819 | Generic | 2026/04/09 | Not stated by source | CDE |
| 华北制药集团新药研究开发有限责任公司;华北制药河北华诺有限公司 | CYHS2602736 | Generic | 2026/11/09 | Not stated by source | CDE |
| 华北制药集团新药研究开发有限责任公司;华北制药河北华诺有限公司 | CYHS2602735 | Generic | 2026/11/09 | Not stated by source | CDE |
API registrations
Non-component matches: 62 companies with A status and 7 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 富马酸伏诺拉生 | M/s Metrochem API Private Limited | Y20260000352 | I | Exact ingredient | 2026/08/13 | CDE |
| 富马酸伏诺拉生 | 安徽鼎旺医药有限公司 | Y20260000476 | I | Exact ingredient | 2026/06/18 | CDE |
| 富马酸伏诺拉生 | 济南明鑫制药股份有限公司 | Y20260000434 | I | Exact ingredient | 2026/06/10 | CDE |
| 富马酸伏诺拉生 | 珠海润都制药股份有限公司 | Y20250000526 | A | Exact ingredient | 2026/11/04 | CDE |
| 富马酸伏诺拉生 | 安徽悦康凯悦制药有限公司 | Y20250000254 | I | Exact ingredient | 2025/06/04 | CDE |
| 富马酸伏诺拉生 | 沧州维智达美制药有限公司 | Y20250000110 | A | Exact ingredient | 2026/09/20 | CDE |
| 醋酸伏诺拉生 | 南京柯菲平制药有限公司 | Y20250000168 | A | Salt-normalized ingredient | 2026/07/30 | CDE |
| 富马酸伏诺拉生 | 汉瑞药业（荆门）有限公司 | Y20250000096 | A | Exact ingredient | 2026/11/04 | CDE |
| 富马酸伏诺拉生 | 山东道合药业有限公司 | Y20240001393 | I | Exact ingredient | 2025/02/19 | CDE |
| 富马酸伏诺拉生 | 辽宁红珊瑚药业有限公司 | Y20240001526 | A | Exact ingredient | 2026/06/24 | CDE |
| 富马酸伏诺拉生 | 潍坊市海欣药业有限公司 | Y20250000007 | A | Exact ingredient | 2026/09/16 | CDE |
| 富马酸伏诺拉生 | 江苏威奇达药业有限公司 | Y20240001506 | A | Exact ingredient | 2026/08/03 | CDE |
| 富马酸伏诺拉生 | 四川伊诺达博医药科技有限公司 | Y20240000967 | A | Exact ingredient | 2026/03/31 | CDE |
| 富马酸伏诺拉生 | 山东方明药业集团股份有限公司 | Y20240001114 | A | Exact ingredient | 2026/08/11 | CDE |
| 富马酸伏诺拉生 | 西安德立生物化工有限公司 | Y20240001081 | A | Exact ingredient | 2026/07/17 | CDE |
| 富马酸伏诺拉生 | 山东铂源药业股份有限公司 | Y20240001140 | A | Exact ingredient | 2026/08/04 | CDE |
| 富马酸伏诺拉生 | 山东罗欣药业集团恒欣药业有限公司 | Y20240001030 | A | Exact ingredient | 2026/07/01 | CDE |
| 富马酸伏诺拉生 | 北京北陆药业股份有限公司 | Y20240000988 | A | Exact ingredient | 2026/02/25 | CDE |
| 富马酸伏诺拉生 | 湖南先施制药有限公司 | Y20240000996 | A | Exact ingredient | 2026/06/16 | CDE |
| 富马酸伏诺拉生 | 浙江京圣药业有限公司 | Y20240000933 | A | Exact ingredient | 2026/05/07 | CDE |
| 富马酸伏诺拉生 | 江西同和药业股份有限公司 | Y20240000857 | A | Exact ingredient | 2026/02/13 | CDE |
| 富马酸伏诺拉生 | 天地恒一制药股份有限公司 | Y20240000949 | A | Exact ingredient | 2025/12/17 | CDE |
| 富马酸伏诺拉生 | 陕西西岳制药（扶风）有限公司 | Y20240000962 | A | Exact ingredient | 2026/06/02 | CDE |
| 富马酸伏诺拉生 | 迪嘉药业集团股份有限公司 | Y20240000683 | A | Exact ingredient | 2026/06/16 | CDE |
| 富马酸伏诺拉生 | 蚌埠丰原涂山制药有限公司 | Y20240000812 | A | Exact ingredient | 2026/05/08 | CDE |
| 富马酸伏诺拉生 | 湖北天舒药业有限公司 | Y20240000846 | A | Exact ingredient | 2026/10/30 | CDE |
| 富马酸伏诺拉生 | 山东鲁抗医药股份有限公司 | Y20240000833 | A | Exact ingredient | 2026/07/16 | CDE |
| 富马酸伏诺拉生 | 江苏天士力帝益药业有限公司 | Y20240000817 | A | Exact ingredient | 2026/03/26 | CDE |
| 富马酸伏诺拉生 | MOREPEN LABORATORIES LIMITED | Y20240000465 | A | Exact ingredient | 2026/06/16 | CDE |
| 富马酸伏诺拉生 | 四川协力制药股份有限公司 | Y20240000192 | A | Exact ingredient | 2025/09/17 | CDE |
| 富马酸伏诺拉生 | 乳源东阳光药业有限公司 | Y20240000028 | A | Exact ingredient | 2026/01/16 | CDE |
| 富马酸伏诺拉生 | 安徽尖峰北卡药业有限公司 | Y20240000050 | A | Exact ingredient | 2026/10/10 | CDE |
| 富马酸伏诺拉生 | 浙江国邦药业有限公司 | Y20240000260 | A | Exact ingredient | 2025/09/28 | CDE |
| 富马酸伏诺拉生 | 无棣融川医药化工科技有限公司 | Y20240000217 | A | Exact ingredient | 2025/10/10 | CDE |
| 富马酸伏诺拉生 | 山东新华制药股份有限公司 | Y20230001353 | A | Exact ingredient | 2025/11/14 | CDE |
| 富马酸伏诺拉生 | 重庆圣华曦药业股份有限公司 | Y20240000072 | A | Exact ingredient | 2025/09/18 | CDE |
| 富马酸伏诺拉生 | AMI LIFESCIENCES PVT. LTD. | Y20240000061 | A | Exact ingredient | 2026/10/10 | CDE |
| 富马酸伏诺拉生 | 无棣融川医药化工科技有限公司 | Y20240000034 | I | Exact ingredient | 2024/03/18 | CDE |
| 富马酸伏诺拉生 | 江西善渊药业有限公司 | Y20230000737 | A | Exact ingredient | 2026/03/18 | CDE |
| 富马酸伏诺拉生 | 山东齐都药业有限公司 | Y20230001272 | A | Exact ingredient | 2025/09/15 | CDE |
| 富马酸伏诺拉生 | 石家庄龙泽制药股份有限公司 | Y20230001396 | A | Exact ingredient | 2025/11/06 | CDE |
| 富马酸伏诺拉生 | 天方药业有限公司 | Y20230001371 | A | Exact ingredient | 2026/06/06 | CDE |
| 富马酸伏诺拉生 | 四川摩尔生物制药有限公司 | Y20230000996 | A | Exact ingredient | 2025/06/26 | CDE |
| 富马酸伏诺拉生 | 重庆天地药业有限责任公司 | Y20230001050 | A | Exact ingredient | 2026/10/30 | CDE |
| 富马酸伏诺拉生 | 浙江九洲药物科技有限公司 | Y20230000921 | A | Exact ingredient | 2026/08/07 | CDE |
| 富马酸伏诺拉生 | 浙江美诺华药物化学有限公司 | Y20230000807 | A | Exact ingredient | 2025/06/09 | CDE |
| 富马酸伏诺拉生 | 连云港润众制药有限公司 | Y20230000731 | A | Exact ingredient | 2025/04/09 | CDE |
| 富马酸伏诺拉生 | 湖南华纳大药厂手性药物有限公司 | Y20230000727 | A | Exact ingredient | 2025/03/14 | CDE |
| 富马酸伏诺拉生 | 云鹏医药集团有限公司 | Y20230000746 | A | Exact ingredient | 2025/08/12 | CDE |
| 富马酸伏诺拉生 | 四川青木制药有限公司 | Y20230000640 | A | Exact ingredient | 2025/02/26 | CDE |
| 富马酸伏诺拉生 | 山东诚汇双达药业有限公司 | Y20230000546 | A | Exact ingredient | 2025/11/18 | CDE |
| 富马酸伏诺拉生 | 福建南方制药股份有限公司 | Y20230000366 | A | Exact ingredient | 2026/03/26 | CDE |
| 富马酸伏诺拉生 | 浙江恒康药业股份有限公司 | Y20230000304 | A | Exact ingredient | 2025/12/04 | CDE |
| 富马酸伏诺拉生 | 浙江赛默制药有限公司 | Y20230000306 | A | Exact ingredient | 2026/06/17 | CDE |
| 富马酸伏诺拉生 | 江苏正济药业股份有限公司 | Y20230000398 | A | Exact ingredient | 2025/12/17 | CDE |
| 富马酸伏诺拉生 | 河北广祥制药有限公司 | Y20230000238 | A | Exact ingredient | 2024/12/13 | CDE |
| 富马酸伏诺拉生 | Takeda Pharmaceutical Company Limited | Y20230000018 | A | Exact ingredient | 2025/07/31 | CDE |
| 富马酸伏诺拉生 | 浙江手心制药有限公司 | Y20220000996 | A | Exact ingredient | 2026/01/05 | CDE |
| 富马酸伏诺拉生 | 齐鲁制药有限公司 | Y20220000970 | A | Exact ingredient | 2024/07/19 | CDE |
| 富马酸伏诺拉生 | 山东朗诺制药有限公司 | Y20220000944 | A | Exact ingredient | 2025/06/06 | CDE |
| 富马酸伏诺拉生 | 四川弘远药业有限公司 | Y20220000654 | A | Exact ingredient | 2024/07/05 | CDE |
| 富马酸伏诺拉生 | 寿光富康制药有限公司 | Y20220000695 | A | Exact ingredient | 2025/04/24 | CDE |
| 富马酸伏诺拉生 | 甘肃海普诺睿创制药有限公司 | Y20220000554 | I | Exact ingredient | 2023/11/02 | CDE |
| 富马酸伏诺拉生 | 宜昌天仁药业有限责任公司 | Y20220000268 | A | Exact ingredient | 2024/04/08 | CDE |
| 富马酸伏诺拉生 | 湖南千金湘江药业股份有限公司 | Y20210001283 | A | Exact ingredient | 2024/04/16 | CDE |
| 富马酸伏诺拉生 | 重庆博腾制药科技股份有限公司 | Y20210001226 | A | Exact ingredient | 2026/04/03 | CDE |
| 富马酸伏诺拉生 | 四川科伦药业股份有限公司 | Y20210000854 | A | Exact ingredient | 2023/05/17 | CDE |
| 富马酸伏诺拉生 | 扬子江药业集团江苏海慈生物药业有限公司 | Y20200001128 | A | Exact ingredient | 2025/12/08 | CDE |
| 富马酸伏诺拉生 | 山东新时代药业有限公司 | Y20190021308 | A | Exact ingredient | 2026/07/07 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/09Accepted
华北制药集团新药研究开发有限责任公司;华北制药河北华诺有限公司
CYHS2602736
Fact date: 2026/11/09 · Site observation date: 2026/11/10
View source ↗ -
2026/11/09Accepted
华北制药集团新药研究开发有限责任公司;华北制药河北华诺有限公司
CYHS2602735
Fact date: 2026/11/09 · Site observation date: 2026/11/10
View source ↗ -
2026/10/26Marketing application approved
海南海灵化学制药有限公司
CYHS2501338 · 国药准字H20266418
Fact date: 2026/10/26 · Publication date: 2026/10/27 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 41 ↗ -
2026/10/26Marketing application approved
海南海灵化学制药有限公司
CYHS2501337 · 国药准字H20266417
Fact date: 2026/10/26 · Publication date: 2026/10/27 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 40 ↗ -
2026/10/24No longer listed under review
扬子江药业集团有限公司
CYHB2601812
Fact date: 2026/10/24 · Site observation date: 2026/10/24
Accepted: 2026/09/24
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/10/23 (approval no.: —; approval date: 2026/10/22); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 31
NMPA · Table row 31 ↗ View source ↗ -
2026/10/24No longer listed under review
扬子江药业集团有限公司
CYHB2601811
Fact date: 2026/10/24 · Site observation date: 2026/10/24
Accepted: 2026/09/24
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/10/23 (approval no.: —; approval date: 2026/10/22); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 30
NMPA · Table row 30 ↗ View source ↗ -
2026/10/22Supplement delivery
扬子江药业集团有限公司
CYHB2601812
Fact date: 2026/10/22 · Publication date: 2026/10/23 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 31 ↗ -
2026/10/22Supplement delivery
扬子江药业集团有限公司
CYHB2601811
Fact date: 2026/10/22 · Publication date: 2026/10/23 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 30 ↗ -
2026/10/20Marketing application approved
浙江诺得药业有限公司
CYHS2500015 · 国药准字H20266341
Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 19 ↗ -
2026/10/20Marketing application approved
浙江诺得药业有限公司
CYHS2500014 · 国药准字H20266340
Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 18 ↗ -
2026/09/24Accepted
-
2026/09/24Accepted
-
2026/09/10Accepted
-
2026/09/10Accepted
-
2026/08/25Accepted
-
2026/08/14Accepted
Takeda Pharmaceutical Company Limited;Takeda Pharmaceutical Company Limited Hikari Plant;Tianjin Takeda Pharmaceutical Company Limited
JYHB2600472
Fact date: 2026/08/14 · Site observation date: 2026/10/22
View source ↗ -
2026/08/14Accepted
Takeda Pharmaceutical Company Limited;Takeda Pharmaceutical Company Limited Hikari Plant
JYHB2600471
Fact date: 2026/08/14 · Site observation date: 2026/10/22
View source ↗ -
2026/08/14Accepted
Takeda Pharmaceutical Company Limited;Takeda Pharmaceutical Company Limited Hikari Plant;Tianjin Takeda Pharmaceutical Company Limited
JYHB2600470
Fact date: 2026/08/14 · Site observation date: 2026/10/22
View source ↗ -
2026/08/14Accepted
Takeda Pharmaceutical Company Limited;Takeda Pharmaceutical Company Limited Hikari Plant
JYHB2600469
Fact date: 2026/08/14 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Vonoprazan Fumarate Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy